Introduction
============

Infections caused by carbapenem-resistant *Klebsiella pneumoniae* (CRKP) isolates are becoming an evolving crisis of global dimensions, especially for pediatric patients, due to high morbidity and mortality.[@b1-idr-11-1935] Carbapenemase production is the main cause of carbapenem resistance; *K. pneumoniae* carbapenemases (KPCs), oxacillinase type 48 (OXA-48), and New Delhi metallo-β-lactamase (MβL) (NDM) carbapenemase have been reported worldwide. The prevalence of each carbapenemase varies geographically, and its resistance profiles also differ. The frequencies of KPC- and NDM-producing *K. pneumoniae* were significantly higher in the USA, Canada, Greece, Taiwan, Colombia, and China, whereas OXA-48-like-producing strains have significantly spread in Turkey and North Africa. In China, despite the extensive spread of KPC-producing strains, NDM-producing *K. pneumoniae* are the type mainly reported in children, though they are rarely found in adults.[@b2-idr-11-1935]--[@b4-idr-11-1935] The detection rate of CRKP isolates in pediatrics increased from 5.3% to 15.9% according to data from the CHINET antimicrobial resistance surveillance program for 2005--2014.[@b5-idr-11-1935] Recently, *K. pneumoniae* isolates producing OXA-232 carbapenemase, a new variant of OXA-48 that was first described in a patient who had traveled from India to France,[@b6-idr-11-1935] were reported in a children's hospital in China.[@b7-idr-11-1935] To date, several countries, such as the UK, Switzerland, Brunei, and Italy,[@b8-idr-11-1935]--[@b11-idr-11-1935] have reported sporadic OXA-232-harboring cases, often emerging together with NDM-1.

Because children are a naturally vulnerable population, carbapenem antibiotics are the first choice for treating infections caused by multidrug-resistant bacteria due to the side effects of other antibiotics, such as fluoroquinolones and aminoglycosides,[@b2-idr-11-1935] and this has led to a burgeoning carbapenem resistance among pathogenic bacteria. The co-harboring of other resistance genes in CRKP has further increased the difficulty of delivering effective antibiotic therapy. Unfortunately, the dearth of effective treatment and extensive use of invasive procedures have increased the incidence of CRKP colonizations or infections and have caused high mortality in patients.[@b12-idr-11-1935],[@b13-idr-11-1935]

Although CRKP has caused wide global disseminations and serious clinical outcomes in pediatric patients, there remained limited data available on the susceptibility and molecular epidemiology of these pathogens in China. Carbapenemase identification greatly aids in targeted drug use and helps to prevent further dissemination. Therefore, we conducted this study to investigate the resistance profiles, molecular epidemiology, and clinical characteristics of CRKP isolates obtained from children in the Shanghai region.

Materials and methods
=====================

Study population and bacterial isolates
---------------------------------------

This retrospective study was conducted in Shanghai Children's Hospital, a 700-bed general university-affiliated hospital, with an estimated population of 2,088,000 patient visits per year. From January 2016 to December 2017, 523 non-duplicated strains of *K. pneumoniae* were isolated from inpatients in our hospital. All isolates were first identified using the matrix-assisted laser desorption ionization-time of flight-mass spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Bremen, Germany). Among these strains, 170 (32.50%) were identified as resistant (zone diameter: ≤19 mm) to imipenem or meropenem by the disk-diffusion method. *Escherichia coli* ATCC 25922 was used as the quality control for identification and antimicrobial susceptibility testing.

This study was approved by the Shanghai Children's Hospital Ethics Committee (Shanghai Jiao Tong University School of Medicine). The Review Board exempted this retrospective study from requiring informed consent because it only focused on the bacteria and did not have an impact on the patients.

Antimicrobial susceptibility testing and phenotypic analysis
------------------------------------------------------------

Antimicrobial susceptibility was determined using the broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI).[@b14-idr-11-1935] Bacterial colonies selected from an 18- to 24-hour agar plate were adjusted to a turbidity equivalent 0.5 McFarland standard and the bacteria suspension was further diluted to a final inoculum density of approximately 10^5^ CFU/mL in each well. Each well of a plate was inoculated with 100 µL inoculum, and the plate was incubated for 24 hours at 35°C. After incubation, the minimum inhibitory concentration (MIC) was read as the lowest concentration of antibiotic at which there was no visible growth. The results were determined and interpreted as follows: colistin according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST),[@b15-idr-11-1935] tigecycline according to the US Food and Drug Administration, and all the others according to the CLSI M100-S27 criteria.[@b14-idr-11-1935] MASTDISCS combi Carba plus disc system D73C (MAST-Carba plus; Mast Group Ltd., Liverpool, UK) was used for the identification of carbapenemase types. Mast D73C is a five-disc detection set comprised of a penem antibiotic-only disc as well as MβL inhibitor, KPC inhibitor, and AmpC inhibitor discs. The fifth disc is a temocillin disc with a MβL inhibitor. D73C can detect MβL-positive strains, KPC-positive strains, and OXA-48-like-positive strains, and it can also differentiate KPC-positive isolates from isolates expressing AmpC coupled with porin loss.

Detection of antimicrobial resistance genes and multilocus sequence typing (MLST)
---------------------------------------------------------------------------------

Polymerase chain reaction (PCR) assays were performed to detect drug resistance genes, such as carbapenemases *(bla~KPC~*, *bla~AIM~*, *bla~GIM~*, *bla~SIM~*, *bla~NDM~*, *bla~IMP~*, *bla~VIM~*, and *bla~OXA-48~*), common extended-spectrum β-lactamase (ESBL) genes (*bla~CTX~* groups, *bla~TEM-1~,* and *bla~SHV~*), AmpC genes (*MOX*, *FOX*, *DHA*, *CIT*, *AAC*, and *EBC*), and plasmid-mediated colistin resistance gene (*MCR-1*), according to previously described conditions and primers.[@b16-idr-11-1935]--[@b19-idr-11-1935] The positive amplicons screened by electrophoresis on a 1.5% agarose gel were sequenced, and the DNA sequences obtained were analyzed and compared with those available in the NCBI GenBank database (<https://www.ncbi.nlm.nih.gov/genbank/>) using BLAST searches.

MLST was performed according to the protocols available at the MLST Pasteur website. Alleles and sequence types (STs) were assigned using the database (<http://bigsdb.pasteur.fr/perl/bigsdb/bigsdb.pl?db=pubmlst_klebsiella_seqdef_public>). Novel alleles and STs were submitted to the administrator of the database and assigned new designations. The eBURST version 3.0 software was used to analyze the clustering of related STs. In this study, isolates were grouped together if six of the seven alleles were homologues.

Clinical and epidemiological data
---------------------------------

Both clinical and epidemiological information were obtained from the medical records of each patient. This information included patient demographics, neonatal birth information, brief hospital course, infection or colonization by CRKP, and underlying and epidemiologic characteristics. CRKP infections and colonizations were defined in accordance with the CDC/NHSN definitions.[@b20-idr-11-1935]

Results
=======

Isolate information
-------------------

During the study period, 523 non-duplicated strains of *K. pneumoniae* were isolated from inpatients in our hospital, of which 170 (32.50%) were identified as CRKP. The percentages of CRKP isolates were 34.47% (101/293) in 2016, and 30.00% (69/230) in 2017. The distribution of carbapenemase-producing *K. pneumoniae* isolates between January 2016 and December 2017 is shown in [Figure 1](#f1-idr-11-1935){ref-type="fig"}. More carbapenemase-producing *K. pneumoniae* isolates were detected between July and December 2016, after which a significant decrease in detection occurred. Later, a substantial increase in detection occurred in December 2017 due to NDM-5-producing *K. pneumoniae* isolates.

Phenotypic characteristics and antimicrobial susceptibility
-----------------------------------------------------------

Phenotypic analysis revealed that of the 170 CRKP isolates, 169 were carbapenemase producers. The remaining isolate expressed AmpC coupled with porin loss. Among the 169 carbapenemase producers, KPC, MβL, and OXA-48-like producers accounted for 17.75% (30/169), 39.65% (67/169), and 42.61% (72/169), respectively. Overall, these 170 CRKP isolates showed high resistance to all tested drugs, especially cephalosporins and carbapenems, except for tigecycline and colistin. The resistance rates of ertapenem, imipenem, and meropenem were 99.41%, 95.88%, and 95.29%, respectively. One isolate was resistant to tigecycline and five isolates were resistant to colistin ([Table 1](#t1-idr-11-1935){ref-type="table"}). Comparative analyses revealed different hydrolysis profiles among the three types of carbapenemase producers. The MβL-producing isolates exhibited a lower resistant rate for amikacin (4.48%), gentamicin (13.43%), nitrofurantoin (35.82%), sulfamethoxazole/ trimethoprim (61.69%), aztreonam (88.06%), ciprofloxacin (11.94%), and levofloxacin (7.46%) than the other two types of carbapenemase producers. In addition, OXA-48-like-producing *K. pneumoniae* isolates showed a lower resistant rate of cefmetazole as well as a relatively lower carbapenem minimum inhibitory concentration ([Table 2](#t2-idr-11-1935){ref-type="table"}).

Genotypes and MLST
------------------

PCR results confirmed that the KPC producers all harbored the *bla~KPC-2~* gene (100%; 30/30), and the OXA-48-like producers all carried the *bla~OXA-232~* gene (100%; 72/72). The *bla~NDM-1~* (53.73%; 36/67), *bla~NDM-5~* (41.79%; 28/67), and *bla~IMP-4~* (4.48%; 3/67) genes were detected in MβL-producing *K. pneumoniae* isolates.

Among these CRKP strains, *bla~OXA-232~*, *bla~KPC-2~*, *bla~NDM-1~*, *bla~NDM-5~*, and *bla~IMP-4~* were detected in 42.35% (72/170), 17.65% (30/170), 20.59% (35/170), 16.47% (28/170), and 1.18% (2/170) of the strains, respectively; additionally, one isolate co-harboring *bla~KPC-2~* and *bla~NDM-1~* and one isolate coharboring *bla~KPC-2~* and *bla~IMP-4~* were identified; no carbapenemase gene was identified in the remaining isolate. The predominant gene was *bla~OXA-232~* in 2016 (54.46%; 55/101) and *bla~NDM-1~* in 2017 (31.88%; 22/69) ([Table 3](#t3-idr-11-1935){ref-type="table"}). The most prevalent ESBL genes were *bla~TEM-1~* (90.59%; 154/170), followed by *bla~CTX-M-15~* (68.24%; 116/170), *bla~SHV-1~* (58.26%; 99/170), *bla~SHV-11~* (30.59%; 52/170), *bla~CTX-M-14~* (14.12%; 24/170), *bla~SHV-12~* (7.65%; 13/170), and *bla~SHV-5~* (0.59%; 1/170). Most isolates harbored more than one ESBL gene (95.88%; 163/170), while seven isolates (4.12%; 7/170) possessed only one ESBL gene. Plasmid-borne AmpC β-lactamases genes, such as *DHA-1* (4.12%; 7/170) and *CMY-6* (1.18%; 2/170), were also found in this study. Fortunately, the recently reported *MCR-1* gene was not detected in any of the isolates from this study.

Sixteen distinct STs were observed among the 170 CRKP isolates. The predominant ST in *CRKP* isolates was ST15 (41.76%; 71/170), followed by ST48 (17.65%; 30/170) and ST11 (17.65%; 30/170) ([Table 4](#t4-idr-11-1935){ref-type="table"}). Three novel alleles (*infB138*, *tonB447*, and *tonB448*) and three novel STs (ST3245, ST3246, and ST3247) were detected in this study. Most isolates carrying *bla~OXA-232~* belonged to ST15; only one belonged to ST3245. Likewise, most CRKP isolates carrying *bla~KPC-2~* belonged to ST11, and only one isolate belonged to ST18. The isolates carrying NDM genes (including *bla~NDM-1~* and *bla~NDM-5~*) belonged to ST14, ST17, ST37, ST43, ST45, ST48, ST105, ST2673, ST3246, and ST3247. The blaIMP-4-positive isolates were observed in two distinct STs (ST101 and ST198). The eBURST analysis indicated that these STs could be clustered into two groups (ST14, ST15, ST3245, and ST3246 in group one; ST17, ST18, and ST3247 in group two) and 10 singletons.

Clinical and epidemiological characteristics
--------------------------------------------

The clinical and epidemiological characteristics of the patients from whom the isolates were obtained are summarized in [Table 5](#t5-idr-11-1935){ref-type="table"}. During the study period, a total of 170 patients developed infections or colonizations caused by CRKP; most of them were male (54.71%; 93/170) and aged less than 3 months (69.41%; 118/170). Most isolates were from respiratory specimens (68.23%; 116/170). The median length of hospital stay was 27 days (12--62 days), and the patients developed CRKP colonization or infection an average of 8 days (4--21 days) after admission.

Most CRKP isolates were detected in the neonatal intensive care unit (NICU) (65.88%; 112/170), followed by the pediatric intensive care unit (PICU) (16.47%; 28/170). Among the NICU patients whose samples were used for this study, the median birth weight was 2090 g (1330--2999 g), and 63.39% (71/112) were classified as premature. A high percentage of these 112 neonates were born via a cesarean delivery (69.64%; 78/112). Additionally, premature membrane rupture, low Apgar score, and history of drug use during pregnancy were reported for a small portion of these neonates, with percentages of 16.96% (19/112), 16.07% (28/112), and 24.11% (27/112), respectively.

Underlying conditions or diseases in the sampled patients are noted in [Table 5](#t5-idr-11-1935){ref-type="table"}. The most common disease was pneumonia (49.41%; 84/170); 54 patients (31.76%) had congenital heart disease, and 18 patients (10.58%) had gastroenteritis. Most patients had a history of invasive procedures, includ ing central venous catheter (78.65%; 132/170), intubation/ mechanical ventilation (75.71%; 127/170), surgery (26.47%; 45/170), urinary catheterization (24.12%; 41/170), and thoracic tube drainage (3.53%; 6/170). Over half of the patients developed CRKP infections (65.88%; 112/170), mainly lower respiratory tract (51.72%; 58/112), and bloodstream (18.75%; 28/112) infections. The remaining patients were colonized by CRKP (34.12%; 58/170), mainly respiratory tract colonization. Carbapenems (44.71%; 76/170) and β-lactam/β-lactamase inhibitor combinations (53.53%; 91/170) were the most frequently used antibiotics before CRKP isolation, whereas third-generation cephalosporin (29.41%; 50/170) was relatively less used.

Discussion
==========

CRKP is a critical threat to pediatric patients, especially neonates, due to limited therapeutic options.[@b1-idr-11-1935] Dissemination of NDM-1-producing *K. pneumoniae* ST76 and ST37 was observed in our hospital between March and June in 2014.[@b2-idr-11-1935] Although NDM-1 was previously reported as the most common type of carbapenemase in children,[@b21-idr-11-1935] our current study revealed that OXA-232 (42.35%; 72/170) was the most prevalent type in our patient population. In China, there are limited epidemiological characteristic data available on pediatric CRKP infections, especially those caused by OXA-232-producing *K. pneumoniae*. In our study, we aimed to provide comprehensive microbial resistance profiles, genotypes, and epidemiological clinical characteristics of CRKP infections mainly caused by OXA-232-producing *K. pneumoniae* isolates, because this information may help to prevent the expanded spread of OXA-232.

Overall, our study showed very high antimicrobial-resistant rates for common antibiotics, except for the low resistant rates for colistin and tigecycline. Notably, the antimicrobial resistance profiles significantly varied among different carbapenemase-producing *K. pneumoniae* isolates. NDM-producing *K. pneumoniae* showed the lowest drug resistance to aminoglycosides and fluroquinolones, a finding which is not consistent with previous reports. In earlier studies, NDM producers were usually also resistant to aminoglycosides as they frequently harbor 16S rRNA methyl-ases.[@b22-idr-11-1935]--[@b24-idr-11-1935] However, aminoglycosides and fluroquinolones are not recommended for pediatrics in China due to their side effects. The rare clinical usage of these drugs in children may be the reason for the low resistance to aminoglycosides and fluroquinolones observed in our study. In contrast, the newly prevalent OXA-232 producers in our hospital were all resistant to aminoglycosides and fluroquinolones. Compared with KPC-2 and NDM producers, OXA-232 producers had lower MIC values for carbapenems, a finding which is in accordance with the reported characteristics of OXA-48.[@b25-idr-11-1935] Indeed, OXA-232 has a weaker ability to hydrolyze imipenem and temocillin than do OXA-48 or OXA-181 in the previous study.[@b6-idr-11-1935] OXA-232 producers are now receiving increasingly more attention because of their higher resistance to most antibiotics than KPC-2 and NDM producers. It is of great urgency to strengthen surveillance and undertake strict infection control measures to prevent a more threatening spread of OXA-232-producing *K. pneumoniae* isolates in China.

Several countries, such as the UK (mainly ST14, ST147, ST231, and ST15),[@b8-idr-11-1935] Switzerland (ST231),[@b9-idr-11-1935] Italy (ST16),[@b11-idr-11-1935] Brunei (ST231),[@b10-idr-11-1935] and Tunisia (ST147),[@b26-idr-11-1935] have reported infections caused by OXA-232-producing *K. pneumoniae* since the initial report of this carbapenemase type in France (ST14).[@b6-idr-11-1935] In China, Yin et al[@b7-idr-11-1935] first reported a small clonal dissemination of OXA-232-producing *K. pneumoniae* among five neonates between April and June 2016. Here, we revealed an outbreak of OXA-232-producing ST15 *K. pneumoniae* involving 72 patients in the NICU. The first OXA-232-producing *K. pneumoniae* in our study was obtained from the sputum of a 2-month-old patient from NICU in March 2016. We speculated that this strain caused the outbreak of OXA-232-producing *K. pneumoniae* in our hospital and even in Shanghai. Most of NDM-5 producers were identified as ST48 (90%; 27/30). NDM-5 has mostly been found in *E. coli*,[@b27-idr-11-1935] and this is the first reported outbreak of NDM-5-producing ST48 *K. pneumoniae* in China. In addition, KPC-2, the predominant carbapenemase among adults in China, was detected in isolates from patients in the PICU and charity ward, and most of these isolates belonged to ST11, which is different from the pandemic sequence type ST258. A single KPC-2-producing *K. pneumoniae* isolate was identified as belonging to ST18. To the best of our knowledge, ST18 *K. pneumoniae* has not been reported before in China.

This study described the monthly distribution of CRKP isolates between January 2016 and December 2017 based on the molecular typing results, and the data suggest that three clonal disseminations of CRKP isolates have occurred in our hospital. KPC-2-producing ST11, OXA-232 producing ST15, and NDM-producing ST48 and ST14 *K. pneumoniae* isolates were responsible to these clonal disseminations at different times. Afterward, a substantial decrease was observed in the number of CRKP infections or colonizations in our hospital. Early detection and strict infection controls may have succeeded in preventing the further dissemination of CRKP during this time. It was worth noting that OXA-232-producing *K. pneumoniae* ST15 gradually disappeared in 2017 while NDM-5-producers appeared. The rapid emergence and spread of NDM-5-producing ST48 *K. pneumoniae* and NDM-1-producing ST37 *K. pneumoniae* in the NICU were observed between November and December 2017. Our study findings support the proposition that high-risk clones should be taken as the major consideration when developing a strategy to prevent the further dissemination of pathogenic isolates.

Most of the patients whose isolates were used in this study had carbapenem exposure and underwent invasive procedures. Previous work has found that antibiotic exposure and invasive procedures were both independent risk factors for developing CRKP infections and colonizations.[@b28-idr-11-1935],[@b29-idr-11-1935] Additionally, a 5-year retrospective case--control study in Turkey showed that 39.0% of CRKP-colonized patients in the PICU and 18.1% of CRKP-colonized patients in the NICU developed systemic CRKP infection after a mean of 10.6±1.9 days following detection of colonization.[@b30-idr-11-1935] During our study period, 34.12% of all cases were identified as CRKP colonizations, and 58.93% (66/112) of infected patients had CRKP colonizations previously. The patients colonized with CRKP should be monitored for the possible further development of CRKP infection. A study performed in China reported that very low birth weight, preterm birth, and total parenteral nutrition were associated with nosocomial infections with carbapenem-resistant Enterobacteriaceae.[@b28-idr-11-1935] In our study, 10.71%, 63.39%, and 67.86% of the neonates had very low birth weight, a preterm birth, and total parenteral nutrition, respectively. When implementing procedures to prevent CRKP infections, patients at high risk should be of the greatest concern.

Limitations
===========

There are several limitations in our study. First, it was performed in a single hospital in Shanghai, and the prevalence and molecular characteristics of CRKP isolates in our pediatric patients may not be generalizable to pediatrics throughout our country. Additionally, our retrospective analysis briefly summarized the clinical characteristics of the patients from whom the CRKP isolates were obtained, and we did not determine independent risk factors for CRKP infections and colonizations, because there has been a lot of relative reports, and our study focused on the resistance phenotype and clinical molecular epidemiology of CRKP.

Conclusions
===========

Our study described the antimicrobial resistance profiles and STs of CRKP isolates from pediatric patients as well as the clinical characteristics of these patients. OXA-232 was identified as being the predominant carbapenemase type in our isolates. Our results highlight the high antimicrobial-resistant rates of OXA-232-producing *K. pneumoniae* compared with CRKP that produces other types of carbapenemase. Furthermore, our data reveal the occurrence of several clonal disseminations in our hospital, which highlights the need to pay more attention to the newly emerging carbapenemase OXA-232 and NDM-5 and to determine which patients are at high risk of infection so that we can promptly take strict precautions.
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###### 

Antimicrobial susceptibility and MIC distributions of CRKP isolates

  Antibiotics   Breakpoint (μg/mL)   MIC (μg/mL)   Antimicrobial susceptibility                                 
  ------------- -------------------- ------------- ------------------------------ ---------- ---------- ------- -------
                                                                                                                
  ETP           ≤0.5                 ≥2            ≤0.25--\>32                    \>32       \>32       99.41   0.59
  IPM           ≤1                   ≥4            1--\>16                        \>16       \>16       95.88   0.59
  MEM           ≤1                   ≥4            1--\>16                        \>16       \>16       95.29   1.76
  CAZ           ≤4                   ≥16           \>32                           \>32       \>32       100     0
  CTX           ≤1                   ≥4            \>32                           \>32       \>32       100     0
  CMZ           ≤16                  ≥64           8--\>64                        \>64       \>64       86.47   8.24
  CXM           ≤4                   ≥32           \>64                           \>64       \>64       100     0
  CSL           ≤16                  ≥64           32--\>128                      \>128      \>128      100     0
  AMK           ≤16                  ≥64           ≤1--\>128                      \>128      \>128      58.24   41.75
  GEN           ≤4                   ≥16           ≤1--\>128                      \>128      \>128      61.76   36.47
  NIT           ≤32                  ≥128          0.5--\>128                     128        \>128      66.47   21.76
  SXT           ≤2/38                ≥4/76         ≤0.25/4.75--\>32/608           \>32/608   \>32/608   81.76   18.24
  ATM           ≤4                   ≥16           ≤1--\>128                      \>128      \>128      94.71   5.29
  CIP           ≤1                   ≥4            ≤0.06--\>8                     4          \>8        62.94   32.35
  LVX           ≤2                   ≥8            ≤0.125--\>16                   16         \>16       61.68   38.32
  TGC           ≤1                   \>2           ≤0.125--2                      0.5        1          0.59    85.88
  COL           ≤2                   \>2           0.25--16                       1          1          2.94    97.06

**Note:** The two sets of data for SXT values show: 1:19 ratio (trimethoprim:sulfamethoxazole).

**Abbreviations:**AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; COL, colistin; CRKP, carbapenem-resistant Klebsiella pneumoniae; CSL, cefoperazone--sulbactam; CTX, cefotaxime; CXM, cefuroxime; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIC, minimum inhibitory concentration; NIT, nitrofurantoin; R, resistance; SXT, sulfamethoxazole/trimethoprim; TGC, tigecycline

###### 

Antimicrobial activity of 17 agents against carbapenemase-producing *Klebsiella pneumoniae* isolates by the microdilution broth method

  Antibiotics   KPC (n=30)              MbL (n=67)   OXA-48 (n=72)                                                                                                   
  ------------- ----------------------- ------------ --------------- ------- ----------------------- -------- ---------- ------- ------------- ---------- ---------- -------
                                                                                                                                                                     
  ETP           \>32                    \>32         \>32            100     16--\>32                \>32     \>32       100     ≤0.25--\>32   \>32       \>32       98.61
  IPM           \>16                    \>16         \>16            100     8--\>16                 \>16     \>16       100     1--\>16       \>16       \>16       90.27
  MEM           \>16                    \>16         \>16            100     16--\>16                \>16     \>16       100     1--\>16       \>16       \>16       88.89
  CAZ           \>32                    \>32         \>32            100     \>32                    \>32     \>32       100     \>32          \>32       \>32       100
  CTX           \>32                    \>32         \>32            100     \>32                    \>32     \>32       100     \>32          \>32       \>32       100
  CMZ           \>64                    \>64         \>64            100     \>64                    \>64     \>64       100     8--\>64       \>64       \>64       68.06
  CXM           \>64                    \>64         \>64            100     \>64                    \>64     \>64       100     \>64          \>64       \>64       100
  CSL           \>128                   \>128        \>128           100     \>128                   \>128    \>128      100     32--\>128     \>128      \>128      100
  AMK           ≤1--\>128               \>128        \>128           76.67   ≤1--\>128               ≤1       ≤1         4.48    ≤1--\>128     \>128      \>128      100
  GEN           ≤1--\>128               \>128        \>128           80      ≤1--\>128               ≤1       ≤1         13.43   ≤1--\>128     \>128      \>128      100
  NIT           0.5--\>128              \>128        \>128           90      8--\>128                64       128        35.82   32--\>128     128        \>128      86.11
  SXT           ≤0.25/4.75-- \>32/608   \>32/608     \>32/608        86.67   ≤0.25/4.75-- \>32/608   32/608   \>32/608   61.19   \>32/608      \>32/608   \>32/608   100
  ATM           \>128                   \>128        \>128           100     ≤1--\>128               \>128    \>128      88.06   32--\>128     128        \>128      100
  CIP           \>8                     \>8          \>8             96.67   ≤0.06--\>8              0.5      4          11.94   \>8           \>8        \>8        100
  LVX           16--\>16                16           \>16            96.67   ≤0.125--\>16            0.5      2          7.46    16--\>16      \>16       \>16       100
  TGC           0.25--2                 0.5          1               0       ≤0.125--2               0.25     0.5        0       ≤0.125--8     1          2          1.39
  COL           0.5--1                  1            1               0       0.5--16                 1        1          1.49    0.25--8       1          1          5.56

**NOTE:** SXT: 1:19 Ratio (trimethoprim:sulfamethoxazole)

**Abbreviations:**AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; COL, colistin; CSL, cefoperazone--sulbactam; CTX, cefotaxime; CXM, cefuroxime; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; NIT, nitrofurantoin; R, resistance; SXT, sulfamethoxazole/ trimethoprim; TGC, tigecycline.

###### 

Distribution of different CRKP genotypes from 2016 to 2017

  Genotype                       2016 (n=101) n (%)   2017 (n=69) n (%)   Total (n=170) n (%)
  ------------------------------ -------------------- ------------------- ---------------------
                                                                          
  *bla~NDM-1~*                   13 (12.87)           22 (31.88)          35 (20.59)
  *bla~NDM-5~*                   10 (9.9)             18 (26.09)          28 (16.47)
  *bla~KPC-2~*                   19 (18.81)           11 (15.94)          30 (17.65)
  *bla~OXA-232~*                 55 (54.46)           17 (24.64)          72 (42.35)
  *bla~IMP-4~*                   2 (1.98)             0                   2 (1.18)
  *bla~KPC-2~ + blaIMP~IMP-4~*   1 (1.0)              0                   1 (0.59)
  *bla~KPC-2~ + blaNDM~NDM-1~*   1 (1.0)              0                   1 (0.59)
  Undetermined                   0                    1 (1.45)            1 (0.59)

**Abbreviation:** CRKP, carbapenem-resistant *Klebsiella pneumoniae.*

###### 

Genotypes and MLST of 170 CRKP isolates

  STs            Resistance genes                        Number of isolates
  -------------- --------------------------------------- --------------------
                                                         
  ST11 (n=30)    KPC-2, TEM-1, SHV-11, CTX-M-14          13
                 KPC-2, TEM-1, SHV-12, CTX-M-14          7
                 KPC-2, SHV-11, CTX-M-14                 5
                 KPC-2, TEM-1, SHV-11                    3
                 KPC-2, SHV-12, CTX-M-14                 2
                 KPC-2, NDM-1, SHV-12, CTX-M-14, CMY-6   1
  ST14 (n=11)    NDM-1, TEM-1, SHV-1, CTX-M-15           7
                 NDM-1, TEM-1, SHV-12, CTX-M-15          2
                 NDM-5, TEM-1, SHV-5, CTX-M-15           1
                 DHA-1, TEM-1, SHV-11, CTX-M-15          1
  ST15 (n=71)    OXA-232, SHV-1, CTX-M-15                71
  ST17 (n=4)     NDM-1, DHA-1, SHV-11, CTX-M-14          2
                 NDM-1, DHA-1, SHV-1, CTX-M-14           1
                 NDM-5, DHA-1, TEM-1, SHV-1, CTX-M-14    1
  ST18 (n=1)     KPC-2, TEM-1, SHV-11, CTX-M-15          1
  ST37 (n=13)    NDM-1, TEM-1, SHV-1                     11
                 NDM-1, SHV-1                            2
  ST43 (n=1)     NDM-1, SHV-12                           1
  ST45 (n=2)     NDM-1, TEM-1, SHV-11, CTX-M-15          1
                 NDM-1, TEM-1, SHV-1                     1
  ST48 (n=30)    NDM-5, SHV-11, CTX-M-15                 27
                 NDM-1, TEM-1, SHV-1, CTX-15             2
                 NDM-1, DHA-1, SHV-11, CTX-M-15          1
  ST101 (n=1)    IMP-4, TEM-1, SHV-1, CTX-M-15           1
  ST105 (n=1)    NDM-1, TEM-1, CTX-M-14                  1
  ST198 (n=1)    IMP-4, SHV-11                           1
  ST2673 (n=1)   KPC-2, IMP-4, DHA-1, TEM-1              1
  ST3245 (n=1)   OXA-232, TEM-1, SHV-1, CTX-M-15         1
  ST3246 (n=1)   NDM-1, TEM-1, SHV-1                     1
  ST3247 (n=1)   NDM-1, SHV-1                            1

**Abbreviations:**CRKP, carbapenem-resistant *Klebsiella pneumoniae*; MLST, multilocus sequence typing; STs, sequence types*.*

###### 

Characteristics of patients colonized or infected by CRKP

  Characteristics                                                                            n=170
  ------------------------------------------------------------------------------------------ -------------------
                                                                                             
  Age (\<3 m)                                                                                118 (69.41)
  Male gender                                                                                93 (54.71)
  Length of hospital stay (days)[a](#tfn8-idr-11-1935){ref-type="table-fn"}                  27 (12--62)
  Length from admission to CRKP isolated (days)[a](#tfn8-idr-11-1935){ref-type="table-fn"}   8 (4--21)
  Neonatal information                                                                       112 (65.88)
  Birth weight (g)[a](#tfn8-idr-11-1935){ref-type="table-fn"}                                2090 (1330--2999)
  Gestational age (weeks)[a](#tfn8-idr-11-1935){ref-type="table-fn"}                         35 (30--39)
  Very low birth weight                                                                      12 (10.71)
  Premature                                                                                  71 (63.39)
  Cesarean/natural vaginal delivery                                                          78 (69.64)
  Premature rupture of membrane                                                              19 (16.96)
  Total parenteral nutrition                                                                 76 (67.86)
  Low Apgar score at 5 minutes (≤7)                                                          18 (16.07)
  History of drug use during pregnancy                                                       27 (24.11)
  GDM                                                                                        5 (4.46)
  PIH                                                                                        7 (6.25)
  Source of isolates                                                                         
  Respiratory                                                                                116 (68.23)
  Urine                                                                                      18 (10.59)
  Blood                                                                                      18 (10.59)
  Secretions                                                                                 7 (4.12)
  Vein detained needle                                                                       3 (1.76)
  Other[b](#tfn9-idr-11-1935){ref-type="table-fn"}                                           8 (4.71)
  Wards of hospitalization                                                                   
  NICU                                                                                       112 (65.88)
  PICU                                                                                       28 (16.47)
  Charity ward                                                                               14 (8.33)
  Gastroenterology                                                                           4 (2.35)
  Respiratory medicine                                                                       4 (2.35)
  Other[c](#tfn10-idr-11-1935){ref-type="table-fn"}                                          8 (4.71)
  Underlying conditions/diseases                                                             
  Pneumonia                                                                                  84 (49.41)
  Congenital heart disease                                                                   54 (31.76)
  Gastroenteritis                                                                            18 (10.58)
  NRDS                                                                                       7 (4.12)
  Invasive procedures                                                                        
  Central venous catheter                                                                    132 (77.65)
  Intubation/mechanical ventilation                                                          127 (75.71)
  Surgery                                                                                    45 (26.47)
  Urinary catheterization                                                                    41 (24.12)
  Thoracic tube drainage                                                                     6 (3.53)
  CRKP colonizations                                                                         58 (34.12)
  CRKP infections                                                                            112 (65.88)
  Lower respiratory tract infection                                                          58 (51.72)
  Bloodstream                                                                                21 (18.75)
  Urinary tract infection                                                                    18 (16.07)
  Intra-abdominal infection                                                                  8 (7.14)
  Skin and soft tissues infection                                                            7 (6.25)
  Antibiotic exposure                                                                        
  Carbapenems                                                                                76 (44.71)
  β-lactam/β-lactamase inhibitor combinations                                                91 (53.53)
  Third generation cephalosporin                                                             50 (29.41)
  Fosfomycin                                                                                 4 (2.35)
  Vancomycin                                                                                 6 (3.53)

**Notes:** Data shown as n (%) unless otherwise specified.

Median and interquartile ranges (25th and 75th percentile).

Other source of isolates, including ascites and pus.

Other wards of hospitalization, including cardiothoracic surgery, cardiovasology, urology, gastroenterology.

**Abbreviations:**CRKP, carbapenem-resistant *Klebsiella pneumoniae;* GDM, gestational diabetes mellitus; m, months; NICU, neonatal intensive care unit; NRDS, neonatal respiratory distress syndrome; PICU, pediatric intensive care unit; PIH, pregnancy induced hypertension; wk, weeks.
